Poster

Treatment Patterns and Persistence Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray

Abstract: BACKGROUND: Durability of esketamine clinical benefits for treatment resistant depression (TRD) may correlate with treatment sessions completed and therapy persistence. Underst...

08/20/2024

Sustained Chorea Improvements with Long-Term, Once-Daily Valbenazine in Adults with Huntington’s Disease

Abstract: Background: In the phase 3 KINECT®-HD (NCT04102579) study, valbenazine significantly improved chorea versus placebo in adults with Huntington’s disease (HD). KINECT®-HD2 (NCT044...

08/20/2024

Switching Patients With Schizophrenia From Intramuscular Paliperidone Palmitate Once Monthly to TV-46000, a Long-Acting Subcutaneous Antipsychotic: An Exploration of Population Pharmacokinetic–Based Strategies

Abstract: Background This analysis used population pharmacokinetic (PopPK) modeling to characterize dosing conversions and switching strategies from intramuscular paliperidone palmitate o...

08/20/2024

Switching Patients With Schizophrenia to TV-46000, a Long-Acting Subcutaneous Antipsychotic, From Risperidone Microspheres (R064766): An Exploration of Population Pharmacokinetic-Based Strategies

Abstract: Background: This analysis used pharmacokinetic (PopPK) modeling to characterize dosing conversions and switching strategies from R064766 (a once-every-2-weeks [q2w] intramuscula...

08/20/2024

Tackling Myths and Misconceptions about Long-Acting Injectables in Schizophrenia

While antipsychotic treatment is essential to achieving and maintaining remission in schizophrenia, conventional antipsychotic treatments are associated with numerous shortcomings, includ...

08/20/2024

The Junonia Postpartum Depression (PPD) Study: Assessing PPD Care Models in the USA

Abstract: Objective: To describe characteristics of patients from a prospective observational study evaluating postpartum depression (PPD) care pathways. Methods: Junonia is an ongoing ...

08/20/2024

Real-world Survey of Clinical Experience using Dexmedetomidine Sublingual Film for Acute Agitation in over 200 Adults with Schizophrenia or Bipolar Disorder

Abstract: Purpose: Agitation treatment in patients with schizophrenia or bipolar disorder is challenging. Alpha-2 agonist, IGALMI™ DSF (dexmedetomidine sublingual film) reduces norepineph...

08/20/2024

Real-World Treatment Experiences and Expectations by Symptom Severity in Patients With Major Depressive Disorder

Abstract: Major Depressive Disorder (MDD) is characterized by depressed mood, anhedonia, and diminished quality of life. The varying severity of MDD symptoms impacts treatment response an...

08/20/2024

Risk of Relapse among Medicare Advantage Members Diagnosed with Schizophrenia and Receiving Once-monthly Paliperidone Palmitate or First Generation Long-acting Injectable Antipsychotics

Abstract: Assessment of real-world outcomes associated with different antipsychotics helps inform treatment selection for patients with schizophrenia. This real-world study aimed to compa...

08/20/2024

Safety and Exposure of TV-46000, a Long-Acting Subcutaneous Antipsychotic (LASCA) Formulation of Risperidone, in Adolescent and Young Adult Patients With Schizophrenia: Results From the Phase 3 RISE and SHINE Studies

Abstract: Background: Two phase 3 trials evaluating TV-46000 for schizophrenia enrolled patients aged 13–65 years. Adolescents aged 13–18 years and young adults aged 19–21 years who recei...

08/20/2024